# Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.

> **NCT01248299** · PHASE2 · TERMINATED · sponsor: **Centre Oscar Lambret** · enrollment: 105 (actual)

## Conditions studied

- Squamous Cell Carcinoma of Esophagus

## Interventions

- **DRUG:** FU-CDDP
- **DRUG:** LV5FU2-CDDP
- **DRUG:** FOLFOX
- **DRUG:** TPF
- **OTHER:** Best Supportive Care

## Key facts

- **NCT ID:** NCT01248299
- **Lead sponsor:** Centre Oscar Lambret
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-01
- **Primary completion:** 2016-01
- **Final completion:** 2017-01
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2019-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01248299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01248299, "Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01248299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*